Department of Psychiatry, University of Michigan, Ann Arbor, and Center for Clinical Management Research, Department of Veterans Affairs Ann Arbor Healthcare System, Ann Arbor.
Psychiatr Serv. 2019 Feb 1;70(2):97-106. doi: 10.1176/appi.ps.201800321. Epub 2018 Dec 17.
Goals were to determine the prevalence of benzodiazepine use (as prescribed and misuse), characterize misuse, and examine variation by age.
A cross-sectional analysis was conducted of 2015 and 2016 National Survey on Drug Use and Health data limited to adults ≥18 (N=86,186) and data from those respondents reporting benzodiazepine use (N=10,290). Measurements included past-year prescription benzodiazepine use and misuse ("any way a doctor did not direct"), substance use disorders, mental illness, and demographic characteristics. Misuse was compared between younger (18-49) and older (≥50) adults.
A total of 30.6 million adults (12.6%) reported past-year benzodiazepine use-25.3 million (10.4%) as prescribed and 5.3 million (2.2%) misuse. Misuse accounted for 17.2% of overall use. Adults ages 50-64 had the highest prescribed use (12.9%). Those ages 18-25 had the highest misuse (5.2%), and those ages ≥65 had the lowest (.6%). Misuse and abuse of or dependence on prescription opioids or stimulants were strongly associated with benzodiazepine misuse. Benzodiazepine misuse without a prescription was the most common type of misuse, and a friend or relative was the most common source. Adults ages ≥50 were more likely than younger adults to use a benzodiazepine more often than prescribed and to use a benzodiazepine to help with sleep.
Benzodiazepine use among U.S. adults was higher than previously reported, and misuse accounted for nearly 20% of use overall. Use by adults ages 50-64 now exceeds use by those ages ≥65. Patients also prescribed stimulants or opioids should be monitored for benzodiazepine misuse. Improved access to behavioral interventions for sleep or anxiety may reduce some misuse.
旨在确定苯二氮䓬类药物(按处方和滥用)的使用流行率,描述滥用情况,并考察年龄差异。
对 2015 年和 2016 年国家药物使用与健康调查数据进行横断面分析,限定对象为≥18 岁的成年人(N=86186),以及报告苯二氮䓬类药物使用情况的应答者数据(N=10290)。测量指标包括过去一年的处方苯二氮䓬类药物使用和滥用(“医生未指示的任何用药方式”)、物质使用障碍、精神疾病和人口统计学特征。比较了年轻(18-49 岁)和年长(≥50 岁)成年人之间的滥用情况。
共有 3060 万成年人(12.6%)报告过去一年苯二氮䓬类药物使用情况,其中 2530 万人(10.4%)按处方使用,530 万人(2.2%)滥用。滥用占总使用量的 17.2%。50-64 岁成年人的处方使用率最高(12.9%)。18-25 岁年龄组的滥用率最高(5.2%),≥65 岁年龄组的滥用率最低(0.6%)。滥用或依赖处方类阿片或兴奋剂与苯二氮䓬类药物滥用密切相关。未经处方滥用苯二氮䓬类药物是最常见的滥用类型,朋友或亲戚是最常见的来源。≥50 岁的成年人比年轻成年人更有可能按处方规定更频繁地使用苯二氮䓬类药物,也更有可能使用苯二氮䓬类药物帮助睡眠。
美国成年人的苯二氮䓬类药物使用量高于此前报告,且滥用占总使用量的近 20%。50-64 岁成年人的使用率现在超过了≥65 岁成年人。同时处方兴奋剂或阿片类药物的患者也应监测苯二氮䓬类药物的滥用情况。改善针对睡眠或焦虑的行为干预措施的可及性可能会减少一些滥用情况。